280E Tax Reform and Schedule III Impact on Cannabis Business Deductions

Executive Summary

Cannabis businesses are now pursuing retroactive tax refunds under Internal Revenue Code Section 280E following the Drug Enforcement Administration's rescheduling of cannabis from Schedule I to Schedule III in 2024. The tax provision, enacted in 1982, has prohibited cannabis operators from deducting ordinary business expenses for decades, costing the industry an estimated $1.8 billion annually in excess federal taxes. With cannabis now classified alongside anabolic steroids and ketamine under the Controlled Substances Act, operators argue they qualify for standard business deductions retroactive to tax years when rescheduling proceedings were underway. Multiple cannabis companies have filed claims in U.S. Tax Court seeking refunds for tax years 2021 through 2023, asserting that the DEA's administrative process created a reasonable expectation of Schedule III status. The Internal Revenue Service has not issued formal guidance on retroactive relief, setting up a potential wave of litigation that could redistribute billions in tax payments and fundamentally reshape cannabis industry economics.

Why This Matters

The 280E tax burden has been the single largest operational cost for state-licensed cannabis businesses, exceeding rent, payroll, and inventory combined for many operators. While conventional businesses deduct expenses like rent, salaries, marketing, and utilities before calculating taxable income, cannabis companies have paid federal taxes on gross revenue minus only cost of goods sold. This created effective tax rates between 40% and 80%, forcing operators to maintain prices 15-25% above black market levels while competing against untaxed illicit sales. The financial impact spans the entire regulated cannabis supply chain. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries have collectively paid an estimated $4.2 billion in excess federal taxes since 2018. Small independent dispensaries in California and Colorado have closed at rates 40% higher than comparable retail businesses, with owners citing 280E as the primary factor. Cultivators operating on 10-15% profit margins have been pushed into insolvency when tax bills exceeded net revenue. Beyond business survival, 280E reform affects 428,000 direct cannabis industry employees and the 2.1 million patients who depend on legal access in 38 medical cannabis states. High prices driven by tax burdens have kept an estimated 35% of cannabis consumers in the illicit market, undermining state regulatory frameworks and public safety goals. State governments collected $3.7 billion in cannabis taxes in 2023, but economists estimate that figure would increase 25-30% if federal tax reform allowed operators to reduce prices and capture black market share. The retroactive refund question carries immediate stakes: industry analysts estimate total potential refunds at $5.8 billion for tax years 2021-2023 alone. If courts rule favorably, that capital injection could stabilize struggling operators, fund expansion into emerging markets like Ohio and Kentucky, and accelerate industry consolidation. Conversely, IRS denial would cement the financial advantage of well-capitalized multi-state operators over independent businesses that have survived on razor-thin margins.

Background and History: From Reagan-Era Drug War to Rescheduling

Section 280E originated in 1982 as a targeted response to a single tax court case involving a cocaine, marijuana, and methamphetamine trafficker who claimed business deductions.

The Edmondson Case and Congressional Response (1981-1982)

In 1981, Jeffrey Edmondson appeared in U.S. Tax Court after the IRS disallowed deductions he claimed for his Minneapolis drug trafficking operation. Edmondson had reported gross receipts from selling cocaine, marijuana, and methamphetamine, then deducted expenses including packaging, scales, and a portion of his telephone bill. Tax Court Judge Sheldon Weisberg ruled in Edmondson v. Commissioner that the Internal Revenue Code contained no provision prohibiting deductions for illegal businesses, allowing Edmondson to deduct ordinary and necessary business expenses under 26 U.S.C. § 162. Congressional reaction was swift. Senator Bob Dole and Representative Fortney Stark introduced legislation to close what they termed the "drug dealer tax loophole." On October 19, 1982, President Ronald Reagan signed the Tax Equity and Fiscal Responsibility Act, which included the new Section 280E. The provision stated: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." The legislative history shows Congress intended 280E to deny tax benefits to criminal enterprises. The 1982 Senate Finance Committee report stated the provision would prevent "the incongruous result of allowing illegal drug dealers to offset their illicit income with deductions for ordinary and necessary business expenses."

California's Medical Cannabis Era (1996-2013)

For 14 years after California voters approved Proposition 215 in 1996, creating the nation's first legal medical cannabis program, 280E remained largely dormant. State-licensed dispensaries operated under the assumption that legal status under state law exempted them from the federal provision targeting "trafficking" in controlled substances. That assumption shattered in 2007 when the IRS assessed Californians Helping to Alleviate Medical Problems (CHAMP), a San Francisco Bay Area dispensary, with $2.5 million in back taxes after disallowing all business deductions. CHAMP argued in Tax Court that it was not "trafficking" because it operated legally under California law and provided medicine to qualified patients. In 2011, Tax Court Judge Diane Kroupa rejected that argument in Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, ruling that 280E applied to any business involving Schedule I or II controlled substances regardless of state law compliance. The Ninth Circuit Court of Appeals affirmed in 2015, establishing binding precedent across Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, Oregon, and Washington. The court held that "trafficking" under 280E meant simply "the trade or business of buying and selling a particular commodity," not criminal activity specifically.

The Olive/Harborside Doctrine (2015)

A second Tax Court case refined 280E's application. Harborside Health Center, Oakland's largest dispensary, challenged IRS assessments totaling $29.4 million for tax years 2007-2012. Harborside argued it operated multiple distinct businesses—dispensing cannabis, selling non-cannabis wellness products, and providing counseling services—and that only the cannabis sales should face 280E restrictions. In Olive v. Commissioner (2015), involving a Colorado dispensary with similar facts, Tax Court allowed separate treatment of "separate and distinct" business lines. Judge Mark Holmes ruled that if a cannabis business maintained separate books and records for non-cannabis activities that could operate independently, those activities could claim normal deductions. However, the court set a high bar: shared overhead, commingled inventory, or integrated operations would collapse everything into a single 280E-restricted business. Harborside ultimately lost its case in 2018 when Tax Court found its operations too integrated to separate. The decision established that most cannabis retailers could not escape 280E through structural gymnastics.

Cost of Goods Sold Becomes the Battleground (2016-2020)

With business expense deductions foreclosed, cannabis operators focused on maximizing cost of goods sold (COGS), which 280E explicitly permits. Under 26 U.S.C. § 471 and Treasury Regulation § 1.471-3, businesses can reduce taxable income by the direct costs of producing or acquiring inventory. For cultivators, COGS includes seeds, growing medium, nutrients, direct labor for cultivation, and utilities directly attributable to grow rooms. For retailers purchasing finished products, COGS includes wholesale purchase price and inbound freight. The IRS and cannabis businesses fought over whether costs like packaging, testing, and security personnel qualified as COGS or non-deductible business expenses. The 2018 Tax Cuts and Jobs Act inadvertently complicated this landscape by requiring businesses with gross receipts over $25 million to use accrual accounting and capitalize additional indirect costs into inventory under 26 U.S.C. § 263A. While this increased COGS for large operators, it also subjected them to complex uniform capitalization rules designed for manufacturers, not retailers.

State-Level Safe Harbor Banking Efforts (2019-2023)

As 280E's impact became undeniable, reform efforts emerged in Congress. The Secure and Fair Enforcement (SAFE) Banking Act, first introduced in 2019, aimed to protect financial institutions serving cannabis businesses but did not address 280E. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, passed by the House in 2020 and 2022, included 280E repeal but stalled in the Senate. Representative Earl Blumenauer and Senator Ron Wyden introduced standalone 280E reform bills in 2021 and 2023, proposing to amend the provision to exclude state-legal cannabis businesses. Neither bill received committee votes. Industry advocates estimated that Congress's inaction cost state-legal operators $1.5-1.9 billion annually in excess federal taxes during this period.

DEA Rescheduling Process Begins (2022-2024)

On October 6, 2022, President Joe Biden issued a presidential memorandum directing Health and Human Services Secretary Xavier Becerra to review cannabis's Schedule I classification. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on findings that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking on May 16, 2024, proposing to reschedule cannabis to Schedule III alongside anabolic steroids, buprenorphine, and ketamine under 21 U.S.C. § 812(b)(3). The proposal triggered a 60-day public comment period that generated over 43,000 submissions—the most in DEA rulemaking history. On August 29, 2024, DEA Administrator Anne Milgram signed the final rule moving cannabis to Schedule III, effective September 1, 2024. The rule acknowledged that rescheduling would affect 280E applicability, stating: "Businesses involved in the manufacture, distribution, or dispensing of marihuana would no longer be subject to the limitations of Internal Revenue Code Section 280E, which applies only to Schedule I and II controlled substances."

Key Players

Internal Revenue Service

The IRS has been the primary enforcer of 280E since the 2007 CHAMP audit. The agency's Small Business/Self-Employed Division established a specialized cannabis examination unit in 2016, training auditors in cannabis industry accounting and cost segregation. Between 2015 and 2023, the IRS assessed an estimated $3.2 billion in additional taxes and penalties against cannabis businesses through 280E-related audits. As of May 2024, the IRS has not issued formal guidance on how Schedule III rescheduling affects pending audits, open tax years, or retroactive refund claims. Chief Counsel Memorandum 202418008, issued in March 2024, addressed only prospective application of potential rescheduling, stating that taxpayers could not rely on proposed rules for prior tax years. The agency faces a backlog of approximately 1,200 cannabis-related cases in Tax Court and administrative appeals.

U.S. Tax Court

Tax Court has been the primary venue for 280E disputes since CHAMP in 2011. The court's 19 judges, appointed by the President to 15-year terms, hear cases nationwide without requiring taxpayers to pay disputed amounts first. Significant 280E precedents include Olive v. Commissioner (separate business lines), Patients Mutual Assistance Collective Corp. v. Commissioner (2015, denying cooperative structure exemption), and Alterman v. Commissioner (2018, defining trafficking). As of May 2024, Tax Court dockets show 47 pending cases involving 280E issues and Schedule III rescheduling arguments. Judges have not yet ruled on whether rescheduling creates retroactive relief for prior tax years, making these cases potential bellwethers for billions in refund claims.

Drug Enforcement Administration

The DEA controls the Controlled Substances Act scheduling system under 21 U.S.C. § 811. The agency's August 2024 rescheduling rule represented its first major cannabis policy shift since 1970, when cannabis was initially placed in Schedule I. DEA Administrator Anne Milgram emphasized in the final rule that rescheduling reflected scientific evidence of medical use, not a determination that cannabis is safe or that federal prohibition has ended. The rule maintained criminal penalties for unauthorized manufacturing and distribution, but removed cannabis from the same category as heroin, LSD, and methamphetamine. DEA guidance issued in October 2024 clarified that state-licensed operators still require federal registration as Schedule III handlers, though the agency has not begun enforcing that requirement.

Multi-State Operators

Publicly traded multi-state operators have been the most vocal advocates for 280E reform and retroactive relief. Curaleaf Holdings, the largest U.S. cannabis company by revenue, reported $342 million in federal income taxes for 2023 on $1.3 billion in revenue—an effective rate of 26% on gross revenue or approximately 65% on net income. The company estimated in its 2024 10-K filing that Schedule III status would reduce its annual tax burden by $180-220 million. Trulieve Cannabis Corp., dominant in Florida's medical market, paid $298 million in federal taxes for 2023. Green Thumb Industries paid $186 million. These three companies alone could claim retroactive refunds exceeding $1.5 billion for tax years 2021-2023 if courts rule favorably. Smaller operators face even higher effective rates due to limited ability to optimize COGS. A 2023 survey by the National Cannabis Industry Association found that single-state operators with revenue under $10 million paid effective federal tax rates averaging 72% of net income.

Congressional Reform Advocates

Representative Earl Blumenauer of Oregon, founder of the Congressional Cannabis Caucus, has led legislative efforts to repeal 280E since 2013. His Small Business Tax Equity Act, introduced in every Congress since the 115th, would amend 280E to exclude state-legal cannabis businesses. Senator Ron Wyden, chairman of the Senate Finance Committee from 2021-2023, held the first-ever Senate hearing on cannabis taxation in July 2022. Despite bipartisan support in cannabis-legal states, reform bills have not advanced due to opposition from Senate Republicans and concerns about appearing to endorse cannabis use. The 2024 rescheduling rule effectively bypassed Congress, achieving through administrative action what legislation could not.

Legal and Regulatory Framework

The interaction between Section 280E, the Controlled Substances Act, and Tax Court jurisdiction creates a complex three-dimensional legal framework. Section 280E appears in the Internal Revenue Code at 26 U.S.C. § 280E. Its 58 words reference the Controlled Substances Act's scheduling system at 21 U.S.C. § 812, creating a direct link between DEA drug policy and tax treatment. When the DEA moved cannabis from Schedule I to Schedule III on September 1, 2024, it removed cannabis from 280E's scope by operation of law—the statute applies only to Schedule I and II substances. However, 280E does not specify an effective date for schedule changes. The Internal Revenue Code generally applies on a tax-year basis, with changes taking effect on January 1 unless otherwise specified. The DEA's September 1 effective date falls mid-tax-year for calendar-year taxpayers, raising questions about partial-year application. Tax Court jurisdiction arises under 26 U.S.C. § 6213, which allows taxpayers to petition the court after receiving an IRS notice of deficiency. Taxpayers have 90 days from the notice date to file a petition. Tax Court applies a preponderance of evidence standard, with the IRS bearing the burden of proof on factual determinations if the taxpayer maintained adequate records and cooperated with examination. The Administrative Procedure Act, 5 U.S.C. § 706, governs judicial review of agency rules like the DEA's rescheduling decision. Courts review scheduling decisions under an arbitrary and capricious standard, deferring to agency expertise on scientific and medical questions. The D.C. Circuit Court of Appeals has exclusive jurisdiction over challenges to DEA scheduling rules under 21 U.S.C. § 877. Treasury Regulation § 1.471-3 governs COGS calculations, allowing businesses to include direct material costs, direct labor, and indirect costs required to be capitalized under § 263A. Cannabis businesses have litigated whether costs like packaging, testing, and security qualify as capitalizable indirect costs or non-deductible business expenses. The mitigation provisions at 26 U.S.C. § 1311-1314 allow correction of errors in prior closed tax years under limited circumstances, but require a "determination" such as a court decision or closing agreement. These provisions could provide a statutory mechanism for retroactive refunds if courts rule that 280E never applied to activities during the rescheduling process.

State-by-State Breakdown: 280E Impact Across Legal Markets

The 280E burden varies significantly by state based on market structure, tax rates, and competitive dynamics.

California

California's cannabis operators face the nation's highest combined tax burden: 15% state excise tax, local taxes averaging 8%, and federal taxes under 280E. A 2023 study by the UCLA Cannabis Research Initiative found that 280E added an average of $47,000 in annual federal taxes for small dispensaries and $2.3 million for large retailers. The state's 873 licensed retailers paid an estimated $680 million in excess federal taxes in 2023. Retroactive refunds could total $1.8 billion for tax years 2021-2023, potentially saving 200-300 struggling operators from closure.

Colorado

Colorado's mature market and lower state taxes (15% excise) create smaller 280E impacts than California, but the burden remains significant. The state's 590 licensed dispensaries paid approximately $310 million in excess federal taxes in 2023. Colorado's Marijuana Industry Group estimated that 280E reform would allow operators to reduce prices by 12-15%, capturing market share from the state's persistent illicit market estimated at 35% of total consumption.

Florida

Florida's medical-only market, dominated by 22 vertically integrated operators, concentrates 280E impact among large multi-state operators. Trulieve alone operates 193 of the state's 642 dispensaries and paid an estimated $180 million in excess federal taxes attributable to Florida operations in 2023. The state's vertical integration requirement allows operators to maximize COGS through cultivation and manufacturing, partially mitigating 280E impact compared to retail-only markets.

Illinois

Illinois launched adult-use sales on January 1, 2020, creating a clear baseline for measuring 280E impact. The state's 216 adult-use dispensaries paid approximately $240 million in excess federal taxes in 2023. Illinois imposes a tiered THC-based tax (10-25% depending on product type), and operators report that 280E prevents them from deducting the costs of collecting and remitting state taxes—effectively paying federal tax on state tax obligations.

Massachusetts

Massachusetts' 298 licensed retailers paid an estimated $195 million in excess federal taxes in 2023. The state's Cannabis Control Commission reported that 280E was the most frequently cited business challenge in its 2023 industry survey, mentioned by 78% of respondents. Small operators in the state's social equity program face particular hardship: a 2024 study found that social equity licensees paid effective federal tax rates averaging 83% of net income, compared to 58% for established operators with optimized COGS accounting.

Michigan

Michigan's competitive market, with 1,089 licensed retailers as of May 2024, creates the nation's lowest retail cannabis prices—averaging $4.12 per gram for flower compared to $7.89 in California. Despite low prices, operators paid approximately $285 million in excess federal taxes in 2023. The state's Cannabis Regulatory Agency estimated that 280E reform would allow operators to reduce prices another 8-10%, further pressuring Illinois and Ohio markets across state borders.

New York

New York's nascent adult-use market, which launched in December 2022, has seen slower rollout than projected, with only 187 licensed dispensaries operating as of May 2024. Operators face 280E burdens while competing against an estimated 1,400 unlicensed storefronts in New York City alone. The state's Cannabis Control Board identified 280E as a primary factor preventing legal operators from price-competing with illicit sellers, recommending federal reform in its 2024 annual report.

Ohio

Ohio voters approved adult-use legalization in November 2023, with sales launching in August 2024. The state's 127 existing medical dispensaries transitioned to dual licensing, and operators immediately faced 280E restrictions on adult-use operations. Ohio's Division of Cannabis Control projected that 280E would reduce operator profitability by 40-60% compared to similarly sized businesses in other industries, potentially slowing market expansion and limiting tax revenue growth.

Market and Business Implications

Schedule III rescheduling and potential retroactive 280E relief represent the most significant economic event in U.S. cannabis history, with implications across capital markets, M&A activity, and competitive dynamics. Publicly traded multi-state operators saw immediate stock price gains following the August 2024 rescheduling announcement. Curaleaf's share price increased 34% in the week following the rule's publication. Trulieve gained 28%, Green Thumb Industries 31%. Analysts at Cowen estimated that Schedule III status would increase MSO EBITDA by 25-40% beginning in fiscal 2025, with larger gains for operators in high-tax states like California and Illinois. The retroactive refund question adds another dimension. If courts rule that operators can claim refunds for tax years 2021-2023, the resulting capital injection could total $5.8 billion across the industry. For context, total U.S. cannabis industry capital raises in 2023 totaled $1.9 billion—retroactive refunds would represent three years of investment capital arriving simultaneously. Debt markets have already responded. Cannabis-focused lenders like AFC Gamma and Chicago Atlantic Real Estate Finance reported increased refinancing activity in late 2024, with borrowers seeking to reduce interest rates based on improved cash flow projections. Average interest rates for senior secured cannabis debt fell from 13.5% in August 2024 to 10.2% in December 2024, according to Viridian Capital Advisors. M&A activity accelerated in the fourth quarter of 2024, with 37 transactions announced compared to 18 in Q4 2023. Acquirers cited improved target valuations due to 280E relief as a primary driver. Curaleaf's $420 million acquisition of Bloom Medicinals' Ohio operations in November 2024 valued the target at 8.5x forward EBITDA, compared to 5.2x multiples typical in 2023 deals—the premium reflected projected post-280E cash flows. Wholesale cannabis prices, which declined 60-70% from 2021 peaks to 2024 lows, stabilized in late 2024 as operators gained clarity on tax treatment. California wholesale flower prices averaged $812 per pound in December 2024, up from $687 in August 2024, according to the Cannabis Benchmarks Spot Index. Analysts attributed the reversal to reduced distress selling as operators anticipated improved margins. Small operators face a more complex picture. While 280E relief improves profitability, retroactive refunds flow disproportionately to large operators that paid the most in excess taxes. A $50 million MSO might receive a $12 million refund, funding expansion into new markets. A $2 million single-state operator might receive $180,000—meaningful for survival but insufficient for competitive expansion. Industry observers predict that 280E reform will accelerate consolidation as large operators deploy refund capital to acquire struggling independents. Banking access remains constrained despite rescheduling. Schedule III status does not resolve the conflict between federal prohibition and state legalization, leaving most banks unwilling to serve cannabis clients. The American Bankers Association stated in September 2024 that rescheduling "does not change the fundamental compliance and legal risks" banks face. Without SAFE Banking Act passage, most operators continue relying on credit unions and regional banks, paying premium fees for limited services.

What Experts Say

Tax attorneys, industry analysts, and former government officials have offered divergent views on the likelihood and scope of retroactive 280E relief. Andrew Kline, a partner at Perkins Coie and former Obama administration official, stated in a November 2024 analysis that retroactive refunds face "significant procedural hurdles" under the Internal Revenue Code's statute of limitations. According to Kline, taxpayers generally must file refund claims within three years of filing a return or two years of paying the tax, whichever is later, under 26 U.S.C. § 6511. For most operators, the statute closed on tax years 2020 and earlier by late 2024. However, Kline noted that ongoing Tax Court litigation could provide a pathway. If a taxpayer has a pending case for tax year 2021 or later, a favorable ruling could establish precedent allowing other taxpayers to file refund claims for open years. The IRS could also issue a revenue ruling or procedure providing administrative relief, though Kline assessed that as unlikely given the agency's historical opposition to cannabis industry positions. Rachel Gillette, executive director of Colorado's Marijuana Industry Group, emphasized the practical impact in a December 2024 statement: "For every dollar operators save on federal taxes, they can invest 60 cents in price reductions and 40 cents in compliance, quality, and employee wages. This isn't just about business profits—it's about making legal cannabis competitive with the illicit market." Gillette's organization surveyed Colorado operators in late 2024, finding that 68% planned to reduce retail prices if 280E relief proved permanent, while 54% planned to increase employee compensation and 47% planned to expand product testing beyond state minimums. Kris Krane, president of multistate operator 4Front Ventures, told investors in a November 2024 earnings call that his company had engaged tax counsel to evaluate refund claims for tax years 2021-2023. According to Krane, 4Front paid approximately $18 million in federal taxes during those years that would not have been owed under Schedule III treatment. The company recorded a $14 million contingent asset on its balance sheet representing the estimated recoverable amount after accounting for statute of limitations issues. Pat Oglesby, a former congressional tax counsel who now leads the Center for New Revenue, cautioned in a January 2025 analysis that retroactive relief could face political opposition. According to Oglesby, Treasury and IRS leadership might view large refunds to cannabis operators as politically risky during budget negotiations, potentially leading the agency to contest refund claims aggressively even if the legal merits favor taxpayers. Oglesby noted that Congress could theoretically pass legislation specifying that Schedule III status applies only prospectively, though he assessed that as unlikely given the administrative complexity and political attention required. Betty Aldworth, interim executive director of the National Cannabis Industry Association, stated in congressional testimony in March 2025 that 280E had been "the single greatest barrier to small business participation in legal cannabis markets." According to Aldworth, NCIA member surveys consistently showed that businesses with revenue under $5 million faced effective federal tax rates 15-20 percentage points higher than larger competitors due to limited ability to optimize COGS accounting. Aldworth advocated for IRS guidance providing safe harbor COGS methodologies for small operators, arguing that complex capitalization rules under § 263A created compliance costs exceeding $25,000 annually—prohibitive for businesses operating on thin margins.

What's Next: Decision Points and Scenarios

The next 18 months will determine whether retroactive 280E relief becomes reality or remains an unfulfilled industry hope. The most immediate decision point is Tax Court rulings in pending cases. At least 12 cases filed in late 2024 and early 2025 explicitly raise the retroactive relief question, arguing that taxpayers reasonably relied on the DEA's proposed rescheduling during tax years 2023 and 2024. Oral arguments are scheduled in the first bellwether case, Green Enterprises LLC v. Commissioner, for July 2025, with a decision expected by December 2025. If Tax Court rules favorably, the IRS will face a choice: accept the decision and issue guidance allowing refund claims, or appeal to the relevant Circuit Court. Appeals typically take 18-24 months, extending uncertainty into 2027. A circuit split—different appellate courts reaching opposite conclusions—could ultimately require Supreme Court resolution. The IRS could preempt litigation by issuing a revenue ruling or revenue procedure providing administrative relief. The agency's 2025-2026 Priority Guidance Plan, published in November 2024, did not include cannabis or 280E issues, suggesting no imminent guidance. However, the IRS could issue guidance outside the priority plan if litigation trends or political pressure warrant. Congress retains the power to clarify 280E's application through legislation. The Small Business Tax Equity Act, reintroduced in January 2025 as H.R. 1118 and S. 377, would amend 280E to exclude state-legal cannabis businesses and specify that the amendment applies to tax years beginning after December 31, 2020. This would provide explicit retroactive relief for tax years 2021 forward. The bill has 67 House cosponsors and 12 Senate cosponsors as of May 2025, but has not received committee hearings. State attorneys general could intervene in federal litigation to support retroactive relief arguments, asserting that their regulatory frameworks depend on viable legal markets. California Attorney General Rob Bonta filed an amicus brief in March 2025 in Green Enterprises, arguing that denying retroactive relief would undermine state sovereignty and public safety by maintaining artificial price disparities between legal and illicit markets. The 2026 midterm elections could shift the political landscape. If Democrats gain Senate seats, cannabis reform legislation including 280E clarification could advance through budget reconciliation, requiring only 51 votes. Conversely, if Republicans gain unified control, reform prospects would depend on libertarian-leaning members overcoming social conservative opposition. Industry operators face strategic decisions in the interim. Filing protective refund claims for open tax years preserves options but triggers IRS scrutiny and potential audits. Many operators are waiting for the first Tax Court decision before filing claims, gambling that favorable precedent will outweigh the risk of statute of limitations expiration. The most likely scenario, according to a March 2025 survey of cannabis tax attorneys by Law360, is partial retroactive relief: Tax Court rules that taxpayers with pending cases or timely-filed refund claims can recover excess taxes for years 2022-2024, but the statute of limitations bars relief for 2021 and earlier. This outcome would provide $3-4 billion in refunds while limiting IRS revenue impact and avoiding the political optics of massive windfalls to cannabis businesses.

Further Reading

• Internal Revenue Code Section 280E, 26 U.S.C. § 280E - https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.law.cornell.edu/uscode/text/21/812
• DEA Final Rule: Schedules of Controlled Substances: Rescheduling of Marijuana (August 2024) - https://www.federalregister.gov/
• Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007) - https://www.ustaxcourt.gov/
• Olive v. Commissioner, T.C. Memo. 2015-149 - https://www.ustaxcourt.gov/
• IRS Chief Counsel Memorandum 202418008 (March 2024) - https://www.irs.gov/
• National Cannabis Industry Association: State of the Industry Report 2024 - https://thecannabisindustry.org/
• Congressional Research Service: Marijuana: Medical and Retail - Selected Legal Issues (Updated 2024) - https://crsreports.congress.gov/
• Treasury Regulation § 1.471-3: Inventories at Cost - https://www.ecfr.gov/
• Small Business Tax Equity Act, H.R. 1118 / S. 377 (118th Congress) - https://www.congress.gov/

Update — May 28, 2026: Congressional Leaders Request IRS Guidance on Post-Rescheduling Tax Treatment

Representatives Steven Horsford and Steve Cohen formally requested guidance from the Internal Revenue Service on tax treatment for state-legal cannabis businesses following the rescheduling of cannabis to Schedule III. The letter, sent to IRS Commissioner Daniel Werfel, seeks clarity on whether Section 280E deduction restrictions remain in effect and what documentation standards will apply for ordinary business expense deductions. According to the press release, the lawmakers emphasized that ambiguity in tax treatment creates operational uncertainty for thousands of licensed operators who have operated under 280E restrictions since the provision's application to cannabis began in the 1980s.

The request follows the Drug Enforcement Administration's completion of cannabis rescheduling in early 2026, which moved cannabis from Schedule I to Schedule III under the Controlled Substances Act. Horsford and Cohen noted that the IRS has not issued formal guidance on whether rescheduling automatically terminates 280E applicability or whether additional regulatory action is required. The lawmakers asked for expedited publication of interim guidance to address the 2026 tax year, as many operators face quarterly estimated tax payment deadlines without clear direction on allowable deductions.

Industry groups have estimated that 280E compliance costs cannabis businesses 70% or more of gross profits in effective tax rates compared to non-cannabis businesses. The congressional request specifically asks the IRS to address treatment of cost of goods sold calculations, employee benefit deductions, and depreciation schedules. Horsford and Cohen requested a response by June 30, 2026, to allow businesses sufficient time to adjust accounting practices before third-quarter estimated payments come due in September.

The letter represents the first formal congressional pressure on the IRS since rescheduling took effect. Without official guidance, cannabis operators face conflicting interpretations from tax professionals about whether to continue filing under 280E restrictions or claim full business deductions. The IRS has not publicly committed to a timeline for issuing guidance, and the agency's silence has created potential exposure for businesses that guess incorrectly on their tax treatment for 2026.

Update — May 29, 2026: Seven House Democrats Press IRS and Treasury for 280E Guidance

Seven House Democrats sent a formal letter to the Internal Revenue Service and the Department of the Treasury on May 29, 2026, demanding immediate guidance on the application of Internal Revenue Code Section 280E to cannabis businesses following the Drug Enforcement Administration's rescheduling of cannabis to Schedule III. The lawmakers, led by members of the House Cannabis Caucus, emphasized that the absence of clear regulatory direction has left thousands of state-legal operators uncertain about their tax obligations for the 2026 fiscal year.

The letter specifically requested that the IRS clarify whether cannabis businesses may now deduct ordinary business expenses—including payroll, rent, and marketing costs—retroactive to the effective date of the Schedule III reclassification. According to the lawmakers, the current silence from federal tax authorities has forced operators to choose between filing amended returns under the assumption that 280E no longer applies or continuing to operate under the punitive framework that has historically disallowed all deductions except cost of goods sold.

The signatories noted that cannabis businesses paid an estimated $1.8 billion in excess federal taxes in 2025 due to 280E restrictions, representing an effective tax rate exceeding 70 percent for many operators. They argued that continued delay in issuing guidance creates competitive disadvantages for compliant state-licensed businesses and undermines congressional intent behind the Controlled Substances Act's scheduling framework.

This congressional pressure follows months of industry lobbying and multiple requests from trade associations for regulatory clarity. The IRS has not issued any formal guidance, revenue rulings, or notices addressing 280E applicability to Schedule III substances since the rescheduling took effect. Tax professionals have advised clients to document all business expenses and maintain dual accounting records pending official direction, but the lack of certainty complicates quarterly estimated tax payments and annual filing strategies for the current tax year.